Rachel Midgely

Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations

Dmitri Mouradov, Enric Domingo, Peter Gibbs et al. · The American Journal of Gastroenterology · 2013 · 150 citations

Medicine, Molecular Genetics, Oncology +16

Assessing menstrual cycles with urinary hormone assays

Nanette Santoro, Sybil L. Crawford, Jenifer E. Allsworth et al. · American Journal of Physiology-Endocrinology and Metabolism · 2003 · 112 citations

Medicine, Endocrinology, Gynecology +15

Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study

Najib M. Rahman, Helen Davies, Marc Salzberg et al. · The Lancet Oncology · 2008 · 34 citations

Medicine, Pharmacokinetics, Pharmacology +10

Phase III Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of Gefitinib versus Placebo in Esophageal Cancer Progressing after Chemotherapy, COG (Cancer Oesophagus Gefitinib)

D. Ferry, S.J. Dutton, Wasat Mansoor et al. · Annals of Oncology · 2012 · 16 citations

Medicine, Oncology, Pharmacology +7

Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?

Kathleen Boyd, Andrew Briggs, Timothy Iveson et al. · Trials · 2011 · 12 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17